The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2012-2024

  Geerts, Dirk ^a   Koster, Jan ^a   Albert, David ^b   Koomoa, Dana Lynn T ^b   Feith, David J ^c   Pegg, Anthony E ^c   Volckmann, Richard ^a   Caron, Huib ^a   Versteeg, Rogier ^a   Bachmann, André S ^b,d,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF HAWAII   (United States)

^e UNIVERSITY OF HAWAII   (United States)

Author keywords

Antizyme 2; Kaplan Meier survival plots; MAD; MAX; MYCN; Neuroblastoma; ODC; Polyamines

Indexed keywords

ANTIZYME; ANTIZYME 1; ANTIZYME 2; ANTIZYME 3; ANTIZYME INHIBITOR 1; ANTIZYME INHIBITOR 2; CARBOXYLYASE; MESSENGER RNA; ONCOPROTEIN; ORNITHINE DECARBOXYLASE; ORNITHINE DECARBOXYLASE INHIBITOR; POLYAMINE; PROTEIN MAD2; PROTEIN MYCN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MAD7; UNCLASSIFIED DRUG; PROTEIN;

AGGRESSION; ARTICLE; CANCER CELL CULTURE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROBLASTOMA; OVERALL SURVIVAL; POLYAMINE METABOLISM; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSCRIPTION REGULATION; ENZYMOLOGY; GENETICS; ONCOGENE MYC; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE AMPLIFICATION; GENES, MYC; HUMANS; NEUROBLASTOMA; ORNITHINE DECARBOXYLASE; PROTEINS; RNA, MESSENGER;

EID: 77949905958     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25074     Document Type: Article

References (47)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-216
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007;369: 2106-2120
3. Cohn SL, Tweddle DA. MYCN amplification remains prognostically strong 20 years after its "clinical debut". Eur J Cancer 2004;40:2639-2642
4. Lu X, Pearson A, Lunec J. The MYCN oncoprotein as a drug development target. Cancer Lett 2003;197:125-130
5. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of a-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-812
6. Pegg AE. Regulation of ornithine decarboxylase. J Biol Chem 2006;281: 14529-14532
7. Casero RA, Jr., Marton LJ. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 2007;6: 373-390
8. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4: 781-792
9. Wallace HM, Fraser AV, Hughes A. A perspective of polyamine metabolism. Biochem J 2003;376:1-14.
10. Shantz LM, Levin VA. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids 2007;33:213-223
11. Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, Gleason MJ, Kim HW. Phase III randomized study of postradiotherapy chemotherapy with combination a- difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 2003;9:981-990
12. Meyskens FL, Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, Albers CG, Ahnen DJ, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-38
13. Seiler N. Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 2003;4: 537-564 (Pubitemid 37139049)
14. Simoneau AR, Gerner EW, Nagle R, Ziogas A, Fujikawa-Brooks S, Yerushalmi H, Ahlering TE, Lieberman R, McLaren CE, Anton-Culver H, Meyskens FL, Jr. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008;17:292-299
15. Ravanko K, Jarvinen K, Paasinen-Sohns A, Holtta E. Loss of p27Kip1 from cyclin E/cyclin-dependent kinase (CDK) 2 but not from cyclin D1/CDK4 complexes in cells transformed by polyamine biosynthetic enzymes. Cancer Res 2000;60:5244-5253
16. Wallick CJ, Gamper I, Thorne M, Feith DJ, Takasaki KY, Wilson SM, Seki JA, Pegg AE, Byus CV, Bachmann AS. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-5618
17. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, Keating J, Thomas W, et al. ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma. Cancer Res 2008; 68:9735-9745
18. Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL. Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma. Cancer Res 2009;69:547-553
19. Matsufuji S, Matsufuji T, Miyazaki Y, Murakami Y, Atkins JF, Gesteland RF, Hayashi S. Autoregulatory frameshifting in decoding mammalian ornithine decarboxylase antizyme. Cell 1995;80: 51-60.
20. Coffino P. Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2001;2:188-194
21. Mangold U. The antizyme family: polyamines and beyond. IUBMB Life 2005; 57:671-676
22. Albeck S, Dym O, Unger T, Snapir Z, Bercovich Z, Kahana C. Crystallographic and biochemical studies revealing the structural basis for antizyme inhibitor function. Protein Sci 2008;17:793-802.
23. Mangold U. Antizyme inhibitor: mysterious modulator of cell proliferation. Cell Mol Life Sci 2006;63:2095-2101
24. Keren-Paz A, Bercovich Z, Porat Z, Erez O, Brener O, Kahana C. Overexpression of antizyme-inhibitor in NIH3T3 fibroblasts provides growth advantage through neutralization of antizyme functions. Oncogene 2006;25:5163-5172
25. Jung MH, Kim SC, Jeon GA, Kim SH, Kim Y, Choi KS, Park SI, Joe MK, Kimm K. Identification of differentially expressed genes in normal and tumor human gastric tissue. Genomics 2000;69:281-286
26. Schaner ME, Davidson B, Skrede M, Reich R, Florenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Trope CG, Kristensen GB, Nesland JM, et al. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 2005;4:26.
27. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005;44: 438-449
28. Kanerva K, Makitie LT, Pelander A, Heiskala M, Andersson LC. Human ornithine decarboxylase paralogue (ODCp) is an antizyme inhibitor but not an arginine decarboxylase. Biochem J 2008; 409:187-192
29. Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Ora I, Versteeg R, Geerts D. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. Exp Cell Res 2008;314:707-719
30. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 2007;35: D760-D765.
31. Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005;102:731-736
32. Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis. Crit Care 2004;8: 389-394
33. Pegg AE, Feith DJ. Polyamines and neoplastic growth. Biochem Soc Trans 2007;35:295-299
34. Darwiche N, Ryscavage A, Perez-Lorenzo R, Wright L, Bae DS, Hennings H, Yuspa SH, Glick AB. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion. Oncogene 2007; 26:6885-6895
35. Tsuji T, Todd R, Meyer C, McBride J, Liao PH, Huang MF, Chou MY, Donoff RB, Wong DT. Reduction of ornithine decarboxylase antizyme (ODC-Az) level in the 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Oncogene 1998;16: 3379-3385
36. Koike C, Chao DT, Zetter BR. Sensitivity to polyamine-induced growth arrest correlates with antizyme induction in prostate carcinoma cells. Cancer Res 1999; 59:6109-6112
37. Miyagawa J, Muguruma M, Aoto H, Suetake I, Nakamura M, Tajima S. Isolation of the novel cDNA of a gene of which expression is induced by a demethylating stimulus. Gene 1999;240: 289-295
38. Chen QR, Bilke S, Wei JS, Whiteford CC, Cenacchi N, Krasnoselsky AL, Greer BT, Son CG, Westermann F, Berthold F, Schwab M, Catchpoole D, et al. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics 2004;5:70.
39. George RE, Kenyon R, McGuckin AG, Kohl N, Kogner P, Christiansen H, Pearson AD, Lunec J. Analysis of candidate gene co-amplification with MYCN in neuroblastoma. Eur J Cancer 1997;33: 2037-2042
40. Lastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-7444
41. Luscher B. Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001;277:1-14.
42. Cetinkaya C, Hultquist A, Su Y, Wu S, Bahram F, Pahlman S, Guzhova I, Larsson LG. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells. Mol Cancer Ther 2007;6:2634-2641
43. Wu S, Pena A, Korcz A, Soprano DR, Soprano KJ. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex. Oncogene 1996;12: 621-629
44. Lazcoz P, Munoz J, Nistal M, Pestana A, Encio IJ, Castresana JS. Loss of heterozygosity and microsatellite instability on chromosome arm 10q in neuroblastoma. Cancer Genet Cytogenet 2007;174:1-8.
45. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V. MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 1997;3 1699-1706
46. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T, Madafiglio J, Marshall GM, Norris MD, Haber M. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 2000;18:3604-3613
47. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N. The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 2006;66: 2826-2833